Phosphore et sédiments: analyse-stockage-relargage-biodisponibilité = Sediments phosphorus: analysis-sorption-desorption-bioavailabilityBONZONGO, Jean-Claude; BERTRU, Georges.1990, 179 pThesis

Availability of metoclopramide in vitro and in vivoVERGIN, H; STROBEL, K; GRÄTZ, J. G. V et al.Archiv der Pharmazie (Weinheim). 1984, Vol 317, Num 2, pp 185-188, issn 0365-6233Article

An in-vivo―in-vitro correlation for the bioavailability of frusemide tabletsKINGSFORD, M; EGGERS, N. J; SOTEROS, G et al.Journal of pharmacy and pharmacology. 1984, Vol 36, Num 8, pp 536-538, issn 0022-3573Article

A new procedure for testing equivalence in comparative bioavailability and other clinical trialsANDERSON, S; HAUCK, W. V.Communications in statistics. Theory and methods. 1983, Vol 12, Num 23, pp 2663-2692, issn 0361-0926Article

Addressing Bioavailability & DigestibilityMERMELSTEIN, Neil H.Food technology (Chicago). 2011, Vol 65, Num 3, pp 76-79, issn 0015-6639, 4 p.Article

Bioavailability of phenolic compoundsKARAKAYA, Sibel.Critical reviews in food science and nutrition. 2004, Vol 44, Num 6, pp 453-464, issn 1040-8398, 12 p.Article

La biodisponibilitéCARON, J; LACROIX, D; LIBERSA, C et al.NPN médecine. 1991, Num 179, pp 524-526, issn 0248-9635Article

Predicting human oral bioavailability of a compound : Development of a novel quantitative structure-bioavailability relationshipANDREWS, C. W; BENNETT, L; YU, L. X et al.Pharmaceutical research. 2000, Vol 17, Num 6, pp 639-644, issn 0724-8741Article

LA DISPONIBILITE BIOLOGIQUE DES MEDICAMENTSHIRTZ J.1976; ACTUAL. PHARMACOL.; FR.; DA. 1976; VOL. 28; PP. 77-106; BIBL. 29 REF.Article

UEBER DIO BIOVERFUEGBARKEIT BEI GELAGERTEN SUPPOSITORIEN: UNTERSUCHUNGEN AM BEISPIEL DES NAPROXEN. II: ZUR BIOVERFUEGBARKEIT DES NAPROXEN BEI GELAGERTEN SUPPOSITORIEN = LA BIODISPONIBILITE DES SUPPOSITOIRES STOCKES: RECHERCHES D'APRES L'EXEMPLE DU NAPROXENE. II: LA BIODISPONIBILITE DU NAPROXENE DANS LES SUPPOSITOIRES ENTREPOSESECKERT T; KNIE U; VAN HUSEN N et al.1982; PHARMAZEUTISCHE INDUSTRIE; ISSN 0031-711X; DEU; DA. 1982; VOL. 44; NO 9; PP. 927-929; ABS. ENG; BIBL. 12 REF.Article

DRUG THERAPY. BIOVAILABILITY OF DRUGS (FIRST OF TWO PARTS) = TRAITEMENT MEDICAMENTEUX. BIOEFFICACITE DES MEDICAMENTS (1RE PARTIE)KOCH WESER J.1974; NEW ENGL. J. MED.; U.S.A.; DA. 1974; VOL. 291; NO 5; PP. 233-237; BIBL. 22REF.Article

Oral bioavailability of flutamide from 1-O-alkylglycerol stabilized o/w nanoemulsionsMADHUSUDHAN, B; RAMBHAU, D; APTE, S. S et al.Journal of dispersion science and technology. 2007, Vol 28, Num 8, pp 1254-1261, issn 0193-2691, 8 p.Article

Increasing bioavailability of iron-fortified foodsTURNER, Elizabeth; BAGRIANSKY, Jack.Food technology (Chicago). 2005, Vol 59, Num 8, pp 74-78, issn 0015-6639, 4 p.Article

Magen-Darm-Passage und Bioverfügbarkeit peroraler Arzneiformen = Le passage gastro-intestinal et la biodisponibilité des formes médicamenteuses per os. Application de la statistique à la description de l'absorption = Gastrointestinal passage and bioavailability of peroral drug forms. Application of statistics in the description of limited absorptionVON GRONING, R.Pharmazeutische Industrie. 1984, Vol 46, Num 1, pp 88-96, issn 0031-711XArticle

Pharmacocinétique: principes fondamentaux = Pharmacokinetics: main principlesLABAUNE, J. P; WEPIERRE, J.1984, 426 p., isbn 2-225-80136-3Book

Amphiphile Arzneistoffe. II: Beziehungen zwischen den kolloidchemischen Eigenschaften und dem pharmazeutisch-technologischen, pharmakokinetischen und pharmakodynamischen Verhalten = Les médicaments amphiphiles. II: Relations entre les propriétés chimiques colloïdales et le comportement technologique pharmaceutique, pharmacocinétique et pharmacodynamique = Amphiphilic drugs. II: Relationships between the colloïdal properties and the technological, pharmacokinetic and pharmacodynamic behavioursTHOMA, K; ALBERT, K.Pharmazie. 1983, Vol 38, Num 12, pp 807-817, issn 0031-7144Article

Nanotechnology for increased micronutrient bioavailabilityJOYE, Iris J; DAVIDOV-PARDO, Gabriel; MCCLEMENTS, David Julian et al.Trends in food science & technology (Regular ed.). 2014, Vol 40, Num 2, pp 168-182, issn 0924-2244, 15 p.Article

Pharmacokinetics and bioavailability of the anti-emetic agent bromoprideBRODIE, R. R; CHASSEAUD, L. F; DARRAGH, A et al.Biopharmaceutics & drug disposition. 1986, Vol 7, Num 3, pp 215-222, issn 0142-2782Article

Circadian changes in carrageenin-induced edema: the anti-inflammatory effect and bioavailability of phenylbutazone in ratsLOUBARIS, N; MICHEL, A; CROS, G et al.Life sciences (1973). 1984, Vol 34, Num 24, pp 2379-2384, issn 0024-3205Article

Enhanced absorption of phenobarbital from suppositories containing phenobarbital povidone coprecipitateIWAOKU, R; OKAMATSU, Y; KINO, S et al.Chemical and pharmaceutical bulletin. 1984, Vol 32, Num 3, pp 1091-1095, issn 0009-2363Conference Paper

Bayesian approach to bioequivalence assessment: an exampleFLUEHLER, H; GRIEVE, A. P; MANDALLAZ, D et al.Journal of pharmaceutical sciences. 1983, Vol 72, Num 10, pp 1178-1181, issn 0022-3549Article

Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studiesLAUFFER, R. B; GREIF, W. L; STARK, D. D et al.Journal of computer assisted tomography. 1985, Vol 9, Num 3, pp 431-438, issn 0363-8715Article

Möglichkeiten zur in-vitro-Beurteilung der Bioverfügbarkeit. IV: Vergleich der Carbamazepinpräparate Finlepsin® und Tegretol® = Evaluation de la biodisponibilité in vitro. IV: comparaison de 2 formes de carbamazépine Finlepsin^® et Tegretol^® = Possibilities of the in vitro evaluation of bioavaibility. IV: comparison of carbamazepine preparations Finlepsin^® and Tegretol^®FÜRST, W; NEUBERT, R; BUCHMANN, E et al.Pharmazie. 1984, Vol 39, Num 3, pp 185-186, issn 0031-7144Article

Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolutionSJOVALL, J; SJOQVIST, R; HUITFELDT, B et al.Journal of pharmaceutical sciences. 1984, Vol 73, Num 2, pp 141-145, issn 0022-3549Article

Rapid quantitative liquid chromatographic determination of caffeine levels in plasma after oral dosingÓCONNELL, S. E; ZURZOLA, F. J.Journal of pharmaceutical sciences. 1984, Vol 73, Num 7, pp 1009-1011, issn 0022-3549Article